ArticleACS chemical neuroscience2020
A Multifunctional Chemical Agent as an Attenuator of Amyloid Burden and Neuroinflammation in Alzheimer's Disease.
Article in ACS chemical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Design, synthesis, biological evaluation, and computational studies of N-benzoylethylenediamine derivatives as cholinesterase inhibitors.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Evaluation of a New Methylimidazole-Containing Thiosemicarbazone as a CuChemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Bifunctional BODIPY-Clioquinol Copper Chelator with Multiple Anti-AD Properties.International journal of molecular sciences · 2025Article
- Donepezil and Memantine Derivatives for Dual-Function and Prodrug Applications in Alzheimer's Disease.ACS chemical neuroscience · 2025Article
- Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer's disease.Translational neurodegeneration · 2025Article
- N-Alkylamino Stilbene Compounds as Amyloid β Inhibitors for Alzheimer's Disease Research.Molecules (Basel, Switzerland) · 2025Article
- Evaluation of Anti-Alzheimer's Potential of Azo-Stilbene-Thioflavin-T derived Multifunctional Molecules: Synthesis, Metal and Aβ Species Binding and Cholinesterase Activity.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- 2-Phenylbenzothiazolyl iridium complexes as inhibitors and probes of amyloid β aggregation.Dalton transactions (Cambridge, England : 2003) · 2024Article
- Detecting the effect of genetic diversity on brain composition in an Alzheimer's disease mouse model.Communications biology · 2024Article
- Article
- Designing multi-target-directed flavonoids: a strategic approach to Alzheimer's disease.Chemical science · 2023Article
- Multipronged diagnostic and therapeutic strategies for Alzheimer's disease.Chemical science · 2022Review
- Turn-on fluorescent sensors for Cu-rich amyloid β peptide aggregates.Sensors & diagnostics · 2022Article
- Amphiphilic Distyrylbenzene Derivatives as Potential Therapeutic and Imaging Agents for Soluble and Insoluble Amyloid β Aggregates in Alzheimer's Disease.Journal of the American Chemical Society · 2021Article
- Pulsed Hydrogen-Deuterium Exchange Reveals Altered Structures and Mechanisms in the Aggregation of Familial Alzheimer's Disease Mutants.ACS chemical neuroscience · 2021Article
- Thioflavin-positive tau aggregates complicating quantification of amyloid plaques in the brain of 5XFAD transgenic mouse model.Scientific reports · 2021Article
- Design of a multivalent bifunctional chelator for diagnosticProceedings of the National Academy of Sciences of the United States of America · 2020Article
- Amentoflavone: A Bifunctional Metal Chelator that Controls the Formation of Neurotoxic Soluble AβACS chemical neuroscience · 2020Article
- Using mass spectrometry-based methods to understand amyloid formation and inhibition of alpha-synuclein and amyloid beta.Mass spectrometry reviewsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disease, and its main hallmark is the deposition of amyloid beta (Aβ) peptides. However, several clinical trials focusing on Aβ-targeting agents have failed recently, and thus new therapeutic leads are focusing on alternate targets such as tau protein pathology, Aβ-metal induced oxidative stress, and neuroinflammation. To address these different pathological aspects of AD, we have employed a multifunctional compound, L1 [4-(benzo[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.